ECE2021 Presented Eposters Presented ePosters 8: Pituitary and Neuroendocrinology (8 abstracts)
Diagnosis and treatment of patients with neuroendocrine tumours: evidence from specialist Polish centres
Marta Bartmanska 1 , Tomasz Bednarczuk 2 , Daria Handkiewicz-Junak 3 , Alicja Hubalewska-Dydejczyk 4 , Grzegorz Kaminski 5 , Agnieszka Kolasinska-Ćwikla 6 , Beata Kos Kudla 7 , Aldona Kowalska 8 , Marek Ruchala 9 & Anhelli Syrenicz 10
1Ipsen Poland; 2Medical University of Warsaw, Department of Internal Medicine and Endocrinology; 3Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Department of Nuclear Medicine and Endocrine Oncology; 4Jagiellonian University, Medical College, Chair and Department of Endocrinology, Cracow, Poland; 5Military Institute of Medicine, Department of Endocrinology and Radioisotope Therapy, Warsaw, Poland; 6Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Warsaw, Poland; 7Medical University of Silesia, Department of Endocrinology and Neuroendocrine Tumors, Department of Pathophysiology and Endocrinology, Katowice, Poland; 8Collegium Medicum, Jan Kochanowski University of Kielce; 9Poznan University of Medical Sciences, Department of Endocrinology, Metabolism and Internal Medicine, Poznan, Poland; 10Pomeranian Medical University, Department of Endocrinology, Metabolic and Internal Diseases, Szczecin, Poland
Background
Optimal management of patients with neuroendocrine tumours (NETs) is essential to ensure the best treatment results. This survey aimed to obtain a comprehensive picture of NET management in Poland by examining the pathway of patients with NETs throughout their diagnosis and treatment.
Methods
Physicians treating patients with NET in 17 Polish clinical centres/hospital wards, covering approximately 80% of patients with NET, were invited to complete an online questionnaire between August 20 and November 3 2020. The survey gathered information about the previous year (2019).
Results
In total, 138 NET specialists from 17 centres (6 oncological; 11 endocrinological), treated 4288 patients with NET in 2019 (27% of whom were newly diagnosed). Four centres managed more than 500 patients, and four managed fewer than 30. Patients were usually referred to NET treatment centres by surgeons, endocrinologists, or oncologists. About half (46%) of all patients with NET in 2019 were diagnosed accidentally. The average time from the first symptoms to diagnosis was 13 months. 54% of newly diagnosed patients with NET were previously misdiagnosed, usually with irritable bowel syndrome, inflammatory bowel disease, or psychosomatic disorders. Only 20% of all managed NETs were functional tumours. The most frequent initial symptoms were pain, diarrhoea, and flushing. The newly diagnosed NETs originated most frequently from the pancreas and midgut, with almost half of the patients presenting with metastases mainly to the liver and/or lymph nodes. After NET diagnosis, 27% of patients were referred to other wards, indicating the need for an interdisciplinary approach to treatment. A delayed treatment strategy (watch & wait) was used in 7% of patients; 36% underwent surgery to remove the primary tumours. 59% of all patients with NET received somatostatin analogues (SSA) as the first-line therapy; 84% who received peptide receptor radionuclide therapy (PRRT) had combined therapy with SSA. The Polish Network of Neuroendocrine Tumours guidelines, followed by the European Neuroendocrine Tumour Society (ENETS) guidelines, were regarded as the most helpful for therapy determination.
Conclusions
Our study provides important insights into the daily management of patient with NET in Poland, and may thereby contribute to the improvement of routine clinical practice and optimization of treatment outcomes.
Volume 73
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more